^
Association details:
Biomarker:PRC2 mutation
Cancer:T Acute Lymphoblastic Leukemia
Drug:JQ-1 (BET inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

BETTING ON PRC2 ALTERATION IN T CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Published date:
05/14/2020
Excerpt:
We treated T-ALL PDXs with the BET protein inhibitor JQ1 and showed that PRC2-altered PDXs are more sensitive than wild-type PDXs to BET inhibition.